FindTrial
Sign In

A study to evaluate whether Myo-inositol improves Kidney recovery in patients with Acute Kidney Injury

Myo inositol supplementation in acute kidney injury a pilot study to assess safety - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/12/099882
Enrollment
45
Registered
2025-12-29
Start date
Unknown
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N179- Acute kidney failure, unspecified

Interventions

Intervention1: Myo-inositol Supplementation: Myo-inositol Supplementation for 1 week in Acute Kidney Injury compared to standard of care and monitoring for 4 months Control Intervention1: Standard of

Sponsors

Dr G Bharani Dharan
Lead Sponsor
DR NUSRAT SHAFIQ
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: All patients between age of 18 and 70 years with the diagnosis of Community-acquired AKI

Exclusion criteria

Exclusion criteria: Patients with Obstructive Nephropathy or biopsy proven/suspected glomerulonephritis as cause of acute kidney injury and those with Decompensated Chronic Liver Disease and Heart failure functional class 3 or 4

Design outcomes

Primary

MeasureTime frame
Safety of Myo-inositol in Patients having Community-acquired AKITimepoint: Daily for 1 week, and weekly for 1 month and monthly after 4 months—

Secondary

MeasureTime frame
Renal recoveryTimepoint: 4 months—

Countries

India

Contacts

Public ContactG Bharani Dharan

Postgraduate Institute of Medical Education and Research, Chandigarh

bharani121095@gmail.com7010397965

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026